News related to Flarex (Fluorometholone Ophthalmic) and/or conditions it is approved for
Bacterial Conjunctivitis Drug Besivance Approved
Source: MedicineNet Pink Eye Specialty [2009.06.01]
Title: Bacterial Conjunctivitis Drug Besivance Approved
Category: Health News
Created: 6/1/2009
Last Editorial Review: 6/1/2009
Pink Eye Pictures Slideshow: Pink Eye (Conjunctivitis)
Source: MedicineNet Eye Allergy Specialty [2008.06.27]
Title: Pink Eye Pictures Slideshow: Pink Eye (Conjunctivitis)
Category: Slideshows
Created: 6/26/2008
Last Editorial Review: 6/27/2008
Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint In A Study Of Adult Subjects With A History Of Grass Pollen Allergies
Source: Allergy News From Medical News Today [2009.11.03]
Schering-Plough Corporation (NYSE: SGP) announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma.
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The American College Of Clinical Pharmacy (ACCP) 2009 Annual Meeting
Source: Allergy News From Medical News Today [2009.10.22]
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.
|
